Safinamide (original) (raw)

dbo:abstract

• سافيناميد (بالإنجليزية: Safinamide)‏ هو دواء يُستعمل في علاج: * مرض باركنسون (ar)
• Safinamid ist der internationale Freiname für einen zugelassenen Wirkstoff zur Behandlung der Parkinson-Krankheit. Chemisch gesehen handelt es sich um ein α-Aminoamid-Derivat. (de)
• La safinamida ( DCI ; nombre comercial Xadago ) es un medicamento que se usa como tratamiento complementario para la enfermedad de Parkinson durante los episodios "apagados"; tiene múltiples modos de acción, incluida la inhibición de la monoamino oxidasa B.​​​ Fue aprobado en Europa en febrero de 2015, ​ en los Estados Unidos en marzo de 2017, ​ y en Canadá en enero de 2019. ​ (es)
• Safinamide (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B. It was approved in the European Union in February 2015, in the United States in March 2017, and in Canada in January 2019. (en)
• La safinamide ( DCI; marchio Xadago ) è un farmaco usato come trattamento aggiuntivo per il morbo di Parkinson con episodi off; ha molteplici modalità d'azione, inclusa l'inibizione della monoamino ossidasi B. È stato approvato nell'Unione Europea nel febbraio 2015, negli Stati Uniti nel marzo 2017, e in Canada nel gennaio 2019. (it)
• Сафинамид это международное наименование действующего вещества медикамента под торговым названием Xadago для лечения болезни Паркинсона. Химически является дериватом альфа-аминоамида. (ru)

dbo:alternativeName

• Xadago, Onstryv (en)

dbo:bioavailability

• 95.000000 (xsd:float)

dbo:casNumber

• 133865-89-1
• 202825-46-5

dbo:chEBI

• 134718

dbo:chEMBL

• 396778
• 48582

dbo:drugbank

• DB06654

dbo:fdaUniiCode

• 90ENL74SIG

dbo:kegg

• D10158
• D10191

dbo:pubchem

• 131682

dbo:thumbnail

• wiki-commons:Special:FilePath/Safinamide.svg?width=300

dbo:wikiPageExternalLink

• https://druginfo.nlm.nih.gov/drugportal/name/safinamide
• https://druginfo.nlm.nih.gov/drugportal/name/safinamide%20mesylate

dbo:wikiPageID

• 18911525 (xsd:integer)

dbo:wikiPageLength

• 19700 (xsd:nonNegativeInteger)

dbo:wikiPageRevisionID

• 1105259982 (xsd:integer)

dbo:wikiPageWikiLink

• dbr:Amidase
• dbr:Pravastatin
• dbr:Epilepsy
• dbr:Blood_plasma
• dbr:Hypertension
• dbr:Pethidine
• dbr:Pharmaceutical_drug
• dbr:Pharmacia
• dbr:Phase_III_clinical_trial
• dbr:Retina
• dbr:Cytochrome_P450
• dbr:Upjohn
• dbr:Uveitis
• dbr:Dopamine_reuptake_inhibitor
• dbr:Dyskinesia
• dbr:Psychomotor_agitation
• dbc:Dopamine_reuptake_inhibitors
• dbc:Fluoroarenes
• dbr:Nausea
• dbr:Oral_administration
• dbr:Ciprofloxacin
• dbr:Elimination_half-life
• dbr:Monoamine_oxidase_inhibitor
• dbr:Mydriasis
• dbr:Orthostatic_hypotension
• dbr:Management_of_Parkinson's_disease
• dbr:Calcium_channel_blocker
• dbr:Zambon
• dbr:Idiopathic_disease
• dbr:Microsome
• dbr:Tricyclic_antidepressant
• dbr:Tyramine
• dbc:Calcium_channel_blockers
• dbc:Monoamine_oxidase_inhibitors
• dbc:Propionamides
• dbc:Serotonin_reuptake_inhibitors
• dbc:Sigma_receptor_ligands
• dbc:Sodium_channel_blockers
• dbr:European_Medicines_Agency
• dbr:Faeces
• dbr:Food_and_Drug_Administration
• dbr:Parkinson's_disease
• dbr:Carboxylic_acid
• dbr:Diabetic_neuropathy
• dbr:Glucuronidation
• dbr:Glucuronide
• dbr:International_Nonproprietary_Name
• dbr:Tetracyclic_antidepressant
• dbr:ABCG2
• dbc:Merck_brands
• dbr:Albinism
• dbr:Kidney
• dbr:Bioavailability
• dbr:Dextromethorphan
• dbr:Diclofenac
• dbr:Dopamine
• dbr:CYP3A4
• dbr:Pitavastatin
• dbr:Placebo
• dbr:Hypertensive_crises
• dbr:Merck-Serono
• dbr:Metabolism
• dbr:Methotrexate
• dbr:Opioids
• dbr:Rasagiline
• dbr:Selective_serotonin_reuptake_inhibitor
• dbr:Selegiline
• dbr:Retinitis_pigmentosa
• dbr:Serotonin_reuptake_inhibitor
• dbr:Serotonin_syndrome
• dbr:Sigma_receptor
• dbr:IC50
• dbr:Sigma-2_receptor
• dbr:Sigma-1_receptor
• dbr:Sodium_channel_blocker
• dbr:Retinopathy
• dbr:Serotonin–noradrenaline_reuptake_inhibitor
• dbr:Monoamine_oxidase_B
• dbr:Merck_KGaA
• dbr:Levodopa
• dbr:Organic_anion_transporter_3
• dbr:Glutamate
• dbr:Farmitalia-Carlo_Erba
• dbr:First-pass_metabolism
• dbr:Plasma_proteins
• dbr:4-[(3-fluorophenyl)methoxy]phenyl]_methylamino]propanamide
• dbr:File:Safinamide_metabolism.svg
• dbr:Newron_Pharmaceuticals

dbp:atcPrefix

• N04 (en)

dbp:atcSuffix

• BD03 (en)

dbp:bioavailability

• 95.0

dbp:c

• 17 (xsd:integer)

dbp:casNumber

• 133865 (xsd:integer)
• 202825 (xsd:integer)

dbp:chebi

• 134718 (xsd:integer)

dbp:chembl

• 48582 (xsd:integer)
• 396778 (xsd:integer)

dbp:chemspiderid

• 116349 (xsd:integer)

dbp:drugbank

• DB06654 (en)

dbp:eliminationHalfLife

• -108000.0

dbp:excretion

• 76 (xsd:integer)

dbp:f

• 1 (xsd:integer)

dbp:h

• 19 (xsd:integer)

dbp:index2Label

• mesylate (en)

dbp:iupacName

• N2-{4-[oxy]benzyl}-(L)-alaninamide (en)

dbp:iupharLigand

• 8291 (xsd:integer)

dbp:kegg

• D10158 (en)
• D10191 (en)

dbp:legalCa

• Rx-only (en)

dbp:legalUk

• POM (en)

dbp:legalUs

• Rx-only (en)

dbp:licenceEu

• yes (en)

dbp:metabolism

• Amidases, glucuronidation (en)

dbp:n

• 2 (xsd:integer)

dbp:o

• 2 (xsd:integer)

dbp:pregnancyCategory

• Fetal malformations in animal studies (en)

dbp:proteinBound

• 88 (xsd:integer)

dbp:pubchem

• 131682 (xsd:integer)

dbp:routesOfAdministration

• dbr:Oral_administration

dbp:smiles

• O=C[C@@H]C (en)

dbp:stdinchi

• 1 (xsd:integer)

dbp:stdinchikey

• NEMGRZFTLSKBAP-LBPRGKRZSA-N (en)

dbp:synonyms

• -2 (xsd:integer)
• EMD-1195686, PNU-15774E; (en)

dbp:tradename

• Xadago, Onstryv (en)

dbp:unii

• 90 (xsd:integer)

dbp:verifiedfields

• changed (en)

dbp:verifiedrevid

• 464386010 (xsd:integer)

dbp:watchedfields

• changed (en)

dbp:width

• 250 (xsd:integer)

dbp:wikiPageUsesTemplate

• dbt:Cite_web
• dbt:Clear_left
• dbt:Drugbox
• dbt:Portal_bar
• dbt:Reflist
• dbt:Short_description
• dbt:Cascite
• dbt:Chemspidercite
• dbt:Drugbankcite
• dbt:Ebicite
• dbt:Fdacite
• dbt:Keggcite
• dbt:Stdinchicite
• dbt:Sigma_receptor_modulators
• dbt:Antiparkinson
• dbt:Drugs.com
• dbt:Ion_channel_modulators
• dbt:Monoamine_reuptake_inhibitors
• dbt:Monoamine_metabolism_modulators

dcterms:subject

• dbc:Dopamine_reuptake_inhibitors
• dbc:Fluoroarenes
• dbc:Calcium_channel_blockers
• dbc:Monoamine_oxidase_inhibitors
• dbc:Propionamides
• dbc:Serotonin_reuptake_inhibitors
• dbc:Sigma_receptor_ligands
• dbc:Sodium_channel_blockers
• dbc:Merck_brands

gold:hypernym

• dbr:Drug

rdf:type

• owl:Thing
• dul:ChemicalObject
• dbo:ChemicalSubstance
• wikidata:Q8386
• yago:WikicatAmines
• yago:Abstraction100002137
• yago:AliphaticCompound114601294
• yago:Amine114739004
• yago:Chemical114806838
• yago:Compound114818238
• yago:Element114840755
• yago:Material114580897
• yago:Matter100020827
• yago:MethaneSeries114951377
• yago:OrganicCompound114727670
• yago:Part113809207
• yago:PhysicalEntity100001930
• yago:Quintessence114847103
• yago:Relation100031921
• dbo:Drug
• yago:Substance100019613
• yago:WikicatPhenolEthers

rdfs:comment

• سافيناميد (بالإنجليزية: Safinamide)‏ هو دواء يُستعمل في علاج: * مرض باركنسون (ar)
• Safinamid ist der internationale Freiname für einen zugelassenen Wirkstoff zur Behandlung der Parkinson-Krankheit. Chemisch gesehen handelt es sich um ein α-Aminoamid-Derivat. (de)
• La safinamida ( DCI ; nombre comercial Xadago ) es un medicamento que se usa como tratamiento complementario para la enfermedad de Parkinson durante los episodios "apagados"; tiene múltiples modos de acción, incluida la inhibición de la monoamino oxidasa B.​​​ Fue aprobado en Europa en febrero de 2015, ​ en los Estados Unidos en marzo de 2017, ​ y en Canadá en enero de 2019. ​ (es)
• Safinamide (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B. It was approved in the European Union in February 2015, in the United States in March 2017, and in Canada in January 2019. (en)
• La safinamide ( DCI; marchio Xadago ) è un farmaco usato come trattamento aggiuntivo per il morbo di Parkinson con episodi off; ha molteplici modalità d'azione, inclusa l'inibizione della monoamino ossidasi B. È stato approvato nell'Unione Europea nel febbraio 2015, negli Stati Uniti nel marzo 2017, e in Canada nel gennaio 2019. (it)
• Сафинамид это международное наименование действующего вещества медикамента под торговым названием Xadago для лечения болезни Паркинсона. Химически является дериватом альфа-аминоамида. (ru)

rdfs:label

• سافيناميد (ar)
• Safinamid (de)
• Safinamida (es)
• Safinamide (it)
• Safinamide (en)
• Сафинамид (ru)

owl:sameAs

• freebase:Safinamide
• yago-res:Safinamide
• wikidata:Safinamide
• dbpedia-ar:Safinamide
• dbpedia-de:Safinamide
• dbpedia-es:Safinamide
• dbpedia-he:Safinamide
• dbpedia-it:Safinamide
• dbpedia-la:Safinamide
• dbpedia-ro:Safinamide
• dbpedia-ru:Safinamide
• dbpedia-sh:Safinamide
• dbpedia-sr:Safinamide
• https://global.dbpedia.org/id/25nDR

prov:wasDerivedFrom

• wikipedia-en:Safinamide?oldid=1105259982&ns=0

foaf:depiction

• wiki-commons:Special:FilePath/Safinamide.svg
• wiki-commons:Special:FilePath/Safinamide_metabolism.svg

foaf:isPrimaryTopicOf

• wikipedia-en:Safinamide

is dbo:wikiPageRedirects of

• dbr:Onstryv
• dbr:Safinamide_methanesulfonate
• dbr:Xadago
• dbr:Safinamide_mesylate

is dbo:wikiPageWikiLink of

• dbr:List_of_adrenergic_drugs
• dbr:List_of_dopaminergic_drugs
• dbr:Onstryv
• dbr:Monoamine_oxidase_inhibitor
• dbr:Zambon
• dbr:Parkinson's_disease
• dbr:ATC_code_N04
• dbr:C17H19FN2O2
• dbr:Ralfinamide
• dbr:Safinamide_methanesulfonate
• dbr:Monoamine_oxidase_B
• dbr:Xadago
• dbr:Safinamide_mesylate

is foaf:primaryTopic of

• wikipedia-en:Safinamide